<DOC>
	<DOCNO>NCT02046460</DOCNO>
	<brief_summary>The primary objective demonstrate non-inferiority treatment ASA anti-coagulant treatment vitamin K antagonists patient cervical artery dissection ( CAD ) .</brief_summary>
	<brief_title>Biomarkers Antithrombotic Treatment Cervical Artery Dissection - TREAT-CAD</brief_title>
	<detailed_description>This randomize control , open label multicenter , non-inferiority trial blind assessment outcome event . Implementation study plan Swiss Stroke Centers Units . Identical investigation perform patient eligible participate study . Imaging : For verification CAD diagnosis , study participant undergo standardized routine MRI scan brain neck study entry . 14 +/- 7 day treatment onset second MRI brain neck perform . The following MRI sequence perform 3 Tesla scanner ( 1 ) spin echo ( SE ) T1w , turbo spin-echo ( TSE ) T2w , FLAIR detect chronic ischemic brain lesion . ( 2 ) Diffusion weight imaging ( DWI ) include apparent diffusion coefficient ( ADC ) map detect acute ischemic brain lesion . ( 3 ) susceptibility-weighted imaging ( SWI ) sequence T2*w gradient echo ( GRE ) detect hemorrhagic brain lesion ( 4 ) contrast-enhanced magnetic resonance angiography ( CE-MRA ) improve delineation wall hematoma perfuse vessel lumen , assess degree obstruction affect artery . MRI scan centrally analyse University Hospital Basel , independently assess two observer blind type treatment clinical outcome . Clinical examination : Patients examine clinically neurologist screen visit , randomization visit , 14 +/- 7 day randomization , 3 month 6 month randomization . At visit , clinical outcome event assess , focal neurological deficit measure use National Institutes Health ( NIH ) Stroke Scale,12 functional level independence use modify Rankin Scale13 . Clinical outcome event independently adjudicate coordinate center Basel , blind type treatment . Blood sample biomarkers analyse do two time ; first soon possible verification CAD-diagnosis second 14 +/- 7 day treatment onset . Measured biomarkers include : MMP9 TIMP2 . The biomarkers analyse multiplex electrochemiluminescent immunosorbent assay . Treatment allocation : Patients randomize receive either Aspirin ( ASA ) anticoagulant ( ratio 1:1 ) . ASA mean Aspirin™ 300 mg q.d . give orally . In patient swallow safely , ASA give intravenously ( e.g . Aspegic™ 250 mg q.d . ) swallow function recover . Anticoagulants mean use vitamin K antagonist ( i.e. , phenprocoumon [ Marcoumar™ ] acenocoumarol [ Sintrom™ ] ) target international normalized ratio ( INR ) 2.0 - 3.0 . Until target INR reach , patient receive anticoagulation i.v . heparin low molecular weight heparin ) . The choice distinct agent ( e.g . phenprocoumon acenocoumarol ) chosen treat physician patient , take account experience agent ( phenprocoumon commonly used German speak part , acenocoumarol usually use French speak part Switzerland ) . Treatment start soon diagnosis establish , informed consent patient next-to-kin obtained baseline magnetic resonance ( MR ) -images perform ( maximum time window maximum 24 hour ) . Treatment duration 90 day +/-14 day ( i.e. , follow-visit 2 ) . Miscellaneous : The patient ask allow usage anonymous study data possible individual patient data meta-analyses future case randomize clinical trial ( RCT ) study subject become available .</detailed_description>
	<mesh_term>Aneurysm , Dissecting</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>1 . Acute ischemic nonischemic symptom within 2 week 2 . Verification CADdiagnosis ( carotid and/or vertebral ) MRtechniques ( least one ) : mural hematoma pseudoaneurysm long filiform stenosis intimal flap double lumen occlusion situate 2 cm bifurcation carotid artery , reveal pseudo aneurysm long filiform stenosis recanalisation . 3 . Written informed consent patient nexttokin 4 . 24h latency period case thrombolysis 5 . Age &gt; 18 year time inclusion 1 . MRcontraindications ( claustrophobia preclude MRI : patient agree undergo MRI scan mild sedation may enter study ) 2 . Contraindications use anticoagulation ( vitamin k antagonist , heparin ) ASA ( accord Swiss `` Arzneimittelkompendium '' http : //www.compendium.ch/search/de judgment treat physician ) 3 . Pregnancy ( Note : woman child bear age pregnancy test do prior study entry )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>